 |
BioWorld-International-2007-08-08
Santhera, Takeda Extend Pact For Idebenone In DMD
Santhera, Takeda Extend Pact For Idebenone In DMD
Santhera Pharmaceuticals AG licensed European rights to idebenone in Duchenne muscular dystrophy (DMD) to Takeda Pharmaceutical Co. Ltd., in return for an up-front payment of €2 million, another €18 million (US$24.6 million) in milestones and royalties on eventual product sales. (BioWorld International)